Travere Therapeutics (TVTX) Competitors

-0.63 (-9.42%)
(As of 05/17/2024 ET)


Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Larimar Therapeutics (LRMR), Astria Therapeutics (ATXS), Verve Therapeutics (VERV), KalVista Pharmaceuticals (KALV), Oculis (OCS), Applied Therapeutics (APLT), Y-mAbs Therapeutics (YMAB), Aerovate Therapeutics (AVTE), Arbutus Biopharma (ABUS), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical preparations" industry.

Travere Therapeutics vs.

Travere Therapeutics (NASDAQ:TVTX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation.

Larimar Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -87.94%. Larimar Therapeutics' return on equity of -35.69% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Travere Therapeutics-87.94% -238.06% -52.87%
Larimar Therapeutics N/A -35.69%-32.21%

In the previous week, Larimar Therapeutics had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 8 mentions for Larimar Therapeutics and 5 mentions for Travere Therapeutics. Larimar Therapeutics' average media sentiment score of 0.84 beat Travere Therapeutics' score of 0.11 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Larimar Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)

Travere Therapeutics received 25 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 60.87% of users gave Larimar Therapeutics an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.

Travere TherapeuticsOutperform Votes
Underperform Votes
Larimar TherapeuticsOutperform Votes
Underperform Votes

Travere Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.

Travere Therapeutics presently has a consensus price target of $16.69, indicating a potential upside of 175.45%. Larimar Therapeutics has a consensus price target of $20.00, indicating a potential upside of 171.00%. Given Travere Therapeutics' higher possible upside, analysts plainly believe Travere Therapeutics is more favorable than Larimar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
0 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
Larimar Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)

91.9% of Larimar Therapeutics shares are held by institutional investors. 3.8% of Travere Therapeutics shares are held by company insiders. Comparatively, 4.3% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Larimar Therapeutics has lower revenue, but higher earnings than Travere Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$145.24M3.18-$111.40M-$2.10-2.89
Larimar TherapeuticsN/AN/A-$36.95M-$0.97-7.61


Larimar Therapeutics beats Travere Therapeutics on 12 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVTX vs. The Competition

MetricTravere TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$461.34M$6.77B$5.32B$7.96B
Dividend YieldN/A2.61%44.08%3.91%
P/E Ratio-2.8918.00137.8017.70
Price / Sales3.18250.582,351.8375.92
Price / CashN/A36.4336.8131.88
Price / Book6.255.895.744.76
Net Income-$111.40M$130.54M$108.91M$217.17M
7 Day Performance-3.81%1.47%1.42%2.90%
1 Month Performance5.94%4.78%4.95%6.66%
1 Year Performance-63.16%-3.69%7.81%9.89%

Travere Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Larimar Therapeutics
1.3669 of 5 stars
+95.8%$502.74MN/A-8.1242Short Interest ↑
Astria Therapeutics
2.0292 of 5 stars
-24.1%$521.10MN/A-4.0959Short Interest ↓
Verve Therapeutics
2.6244 of 5 stars
-63.4%$523.07M$11.76M-2.17255Insider Buying
News Coverage
KalVista Pharmaceuticals
3.9311 of 5 stars
1.2118 of 5 stars
+0.6%$492.48M$980,000.00-6.8336Analyst Revision
Applied Therapeutics
4.5895 of 5 stars
+177.5%$530.20M$-477,000.00-2.5225Short Interest ↓
Y-mAbs Therapeutics
2.1891 of 5 stars
Aerovate Therapeutics
1.2241 of 5 stars
+7.3%$537.91MN/A-6.6951Analyst Forecast
Insider Selling
Analyst Revision
News Coverage
Arbutus Biopharma
1.3512 of 5 stars
+19.2%$539.73M$12.99M-6.5073Short Interest ↑
News Coverage
Adlai Nortye
1.0703 of 5 stars
N/A$479.70MN/A0.00127Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:TVTX) was last updated on 5/19/2024 by Staff

From Our Partners